Relationships between serum lipids, CA153 level and breast cancer incidence and clinicopathological features of patients

Abstract

Abstract:

ObjectiveTo explore the relationships between serum lipids, CA153 level and breast cancer incidence and clinicopathological features of patients.MethodsA total of 198 patients with breast cancer diagnosed and treated at Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School were enrolled as the case group, and 198 healthy women were selected with 1∶1 age pairing as controls. Five milliliters of fasting venous blood was collected to measure serum lipids levels in all subjects and CA153 levels in breast cancer patients. The difference of serum lipids levels between the two groups was compared. Logistic regression model was used to analyze the risk factors of breast cancer. For 165 breast cancer patients who did not receive neoadjuvant chemotherapy, independent samplet-test was used to compare serum lipids and CA153 levels in breast cancer patients with different pathological features, and Pearson correlation analysis was used to calculate the correlation between variables and CA153.ResultsThe triglyceride (TG) levels in the case group and the control group were (1.22±0.73) mmol/L and (1.06±0.52) mmol/L respectively, and the difference was statistically significant (t=2.559,P=0.011); the total cholesterol (TC) levels were (4.47±0.86) mmol/L and (4.99±0.80) mmol/L respectively, and the difference was statistically significant (t=-6.228,P<0.001); the high-density lipoprotein cholesterol (HDL-C) levels were (1.32±0.34) mmol/L and (1.53±0.38) mmol/L respectively, and the difference was statistically significant (t=-5.913,P<0.001). Higher TC and HDL-C levels were independent protective factors for breast cancer (OR=0.350,P<0.001;OR=0.531,P=0.013). The TC levels in lymph node positive and lymph node negative patients were (4.36±0.73) mmol/L and (4.67±0.83) mmol/L respectively, and the difference was statistically significant (t=-2.518,P=0.013); low-density lipoprotein cholesterol (LDL-C) levels were (2.53±0.58) mmol/L and (2.77±0.70) mmol/L respectively, and the difference was statistically significant (t=-2.312,P=0.022). The TC levels in patients with stage Ⅰ and stage Ⅱ/Ⅲ were (4.90±0.89) mmol/L and (4.46±0.76) mmol/L respectively, and the difference was statistically significant (t=2.855,P=0.005); LDL-C levels were (2.95±0.71) mmol/L and (2.60±0.63) mmol/L respectively, and the difference was statistically significant (t=2.705,P=0.008). The level of CA153 in triple-negative breast cancer patients [(14.94±7.45) U/ml] was significantly higher than that in non-triple-negative breast cancer patients [(11.96±5.96) U/ml], and the difference was statistically significant (t=2.359,P=0.020). The level of CA153 was positively correlated with the level of TG (r=0.167,P=0.032).ConclusionDyslipidemia is associated with an increased risk of breast cancer. The levels of serum lipids vary among patients with different lymph node status and tumor stages. CA153 level is positively correlated with TG level to some extent.

Key words:Breast neoplasms,Dyslipidemias,Triglycerides,Cholesterol,CA153

Zhao Yixin, Guan Yinan, Zhang Yin, Shi Xianbiao, Yao Yongzhong. Relationships between serum lipids, CA153 level and breast cancer incidence and clinicopathological features of patients[J]. Journal of International Oncology, 2020, 47(2): 70-76.

Figures/Tables6

临床特征	病例组 (n=198)	对照组 (n=198)	t值	P值
年龄(岁)	51.89±9.62	52.01±9.68	-0.115	0.909
身高(cm)	159.33±5.66	159.74±5.21	-0.744	0.457
体重(kg)	60.79±8.78	59.60±7.74	1.431	0.153
BMI(kg/m²)	23.94±3.16	23.37±2.99	1.825	0.069
TG(mmol/L)	1.22±0.73	1.06±0.52	2.559	0.011
TC(mmol/L)	4.47±0.86	4.99±0.80	-6.228	<0.001
HDL-C(mmol/L)	1.32±0.34	1.53±0.38	-5.913	<0.001
LDL-C(mmol/L)	2.65±0.68	2.62±0.61	0.466	0.642

变量	OR值	95%CI	P值
TG(mmol/L)
≥1.240	1.585	1.038~2.421	0.033
<1.240	参考
TC(mmol/L)
≥4.775	0.332	0.220~0.500	<0.001
<4.775	参考
HDL-C(mmol/L)
≥1.325	0.388	0.256~0.588	<0.001
<1.325	参考
LDL-C(mmol/L)
≥3.275	1.429	0.844~2.421	0.184
<3.275	参考
月经状态
已绝经	1.224	0.825~1.816	0.315
未绝经	参考
年龄	0.999	0.979~1.019	0.909
BMI	1.062	0.995~1.133	0.070

临床病理特征	例数	百分比(%)
肿瘤大小
T₁	51	30.9
T₂	105	63.6
T₃	9	5.5
淋巴结分期
N₀	95	57.6
N₁	50	30.3
N₂	12	7.3
N₃	8	4.8
临床分期
Ⅰ	31	18.8
Ⅱ	111	67.3
Ⅲ	23	13.9
分子分型
Luminal A型	9	5.5
Luminal B型	97	58.8
Her-2过表达型	29	17.6
三阴性	30	18.2

临床病理特征	淋巴结转移		t值	P值	临床分期		t值	P值
临床病理特征	阳性(n=70)	阴性(n=95)	t值	P值	Ⅰ期(n=31)	Ⅱ、Ⅲ期(n=134)	t值	P值
TG(mmol/L)	1.27±0.81	1.17±0.71	0.784	0.434	1.19±0.65	1.22±0.78	-0.217	0.828
TC(mmol/L)	4.36±0.73	4.67±0.83	-2.518	0.013	4.90±0.89	4.46±0.76	2.855	0.005
HDL-C(mmol/L)	1.28±0.32	1.38±0.35	-1.763	0.080	1.41±0.29	1.32±0.35	1.327	0.186
LDL-C(mmol/L)	2.53±0.58	2.77±0.70	-2.312	0.022	2.95±0.71	2.60±0.63	2.705	0.008
CA153(U/ml)	12.57±6.68	12.46±6.11	0.105	0.916	11.86±5.58	12.66±6.52	-0.629	0.530
临床病理特征	分子分型		t值	P值	肿瘤大小		t值	P值
临床病理特征	三阴性(n=30)	非三阴性(n=135)	t值	P值	T₁(n=51)	T₂、T₃(n=114)	t值	P值
TG(mmol/L)	1.20±0.64	1.22±0.78	-0.137	0.892	1.21±0.65	1.21±0.80	0.006	0.996
TC(mmol/L)	4.68±0.86	4.51±0.79	1.073	0.285	4.66±0.92	4.48±0.74	1.327	0.186
HDL-C(mmol/L)	1.28±0.36	1.35±0.34	-0.953	0.342	1.36±0.32	1.33±0.35	0.521	0.603
LDL-C(mmol/L)	2.84±0.73	2.63±0.64	1.530	0.128	2.77±0.71	2.62±0.64	1.335	0.184
CA153(U/ml)	14.94±7.45	11.96±5.96	2.359	0.020	12.36±6.34	12.57±6.37	-0.202	0.840

变量	CA153水平
年龄	0.025	0.752
BMI	0.150	0.055
TG	0.167	0.032
TC	0.010	0.896
HDL-C	-0.149	0.056
LDL-C	0.013	0.869

References35

[1]	Siegel RL, Miller KD, Jemal A , et al. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68(1):7-30. DOI: 10.3322/caac.21442.
[2]	Chen W, Zheng R, Baade PD , et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338.
[3]	Ikonen E . Cellular cholesterol trafficking and compartmentalization[J]. Nat Rev Mol Cell Biol, 2008,9(2):125-138. DOI: 10.1038/nrm2336.
[4]	Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N , et al. Major lipids, apolipoproteins, and risk of vascular disease[J]. JAMA, 2009,302(18):1993-2000. DOI: 10.1001/jama.2009.1619.
[5]	His M, Zelek L, Deschasaux M , et al. Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk[J]. Eur J Epidemiol, 2014,29(2):119-132. DOI: 10.1007/s10654-014-9884-5.
[6]	Capasso I, Esposito E, Pentimalli F , et al. Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience[J]. Cancer Biol Ther, 2010,10(12):1240-1243. DOI: 10.4161/cbt.10.12.13473.
[7]	Bianchini F, Kaaks R, Vainio H , et al. Overweight, obesity, and cancer risk[J]. Lancet Oncol, 2002,3(9):565-574. DOI: 10.1016/s1470-2045(02)00849-5.
[8]	Agnoli C, Berrino F, Abagnato CA , et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study[J]. Nutr Metab Cardiovasc Dis, 2010,20(1):41-48. DOI: 10.1016/j.numecd.2009.02.006.
[9]	Sandri MT, Salvatici M, Botteri E , et al. Prognostic role of CA15.3 in 7942 patients with operable breast cancer[J]. Breast Cancer Res Treat, 2012,132(1):317-326. DOI: 10.1007/s10549-011-1863-x.
[10]	Edge SB, Compton CC . The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010,17(6):1471-1474. DOI: 10.1245/s10434-010-0985-4.
[11]	Goldhirsch A, Winer EP, Coates AS , et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013[J]. Ann Oncol, 2013,24(9):2206-2223. DOI: 10.1093/annonc/mdt303.
[12]	McPherson K, Steel CM, Dixon JM , et al. ABC of breast diseases: breast cancer-epidemiology, risk factors, and genetics[J]. BMJ, 2000,321(7261):624-628. DOI: 10.1136/bmj.321.7261.624.
[13]	Agurs-Collins T, Kim KS, Dunston GM , et al. Plasma lipid alterations in African-American women with breast cancer[J]. J Cancer Res Clin Oncol, 1998,124(3-4):186-190. DOI: 10.1007/s004320050153.
[14]	Takatani O, Okumoto T, Kosano H , et al. Genesis of breast cancer in Japanese: a possible relationship between sex hormone binding globulin (SHBG) and serum lipid components[J]. Breast Cancer Res Treat 1991,18 Suppl 1: S27-S29. DOI: 10.1007/BF02633523.
[15]	Saavedra-García P, Nichols K, Mahmud Z , et al. Unravelling the role of fatty acid metabolism in cancer through the FOXO3-FOXM1 axis[J]. Mol Cell Endocrinol, 2018,462(Pt B):82-92. DOI: 10.1016/j.mce.2017.01.012. doi:10.1016/j.mce.2017.01.012
[16]	Melvin JC, Seth D, Holmberg L , et al. Lipid profiles and risk of breast and ovarian cancer in the Swedish AMORIS study[J]. Cancer Epidemiol, Biomarkers Prev, 2012,21(8):1381-1384. DOI: 10.1158/1055-9965.EPI-12-0188.
[17]	Touvier M, Fassier P, His M , et al. Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies[J]. Br J Nutr, 2015,114(3):347-357. DOI: 10.1017/S000711451500183X.
[18]	Boyd NF , McGuire V. Evidence of association between plasma high-density lipoprotein cholesterol and risk factors for breast cancer[J]. J Natl Cancer Inst, 1990,82(6):460-468. DOI: 10.1093/jnci/82.6.460.
[19]	Kitahara CM , Berrington de González A, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea[J]. J Clin Oncol, 2011,29(12):1592-1598. DOI: 10.1200/JCO.2010.31.5200.
[20]	Vitols S, Gahrton G, Björkholm M , et al. Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia[J]. Lancet, 1985,2(8465):1150-1154. DOI: 10.1016/s0140-6736(85)92679-0.
[21]	Dessi S, Batetta B, Pulisci D , et al. Altered pattern of lipid metabolism in patients with lung cancer[J]. Oncology, 1992,49(6):436-441. DOI: 10.1159/000227088.
[22]	Schatzkin A, Hoover RN, Taylor PR , et al. Site-specific analysis of total serum cholesterol and incident cancer in the national health and nutrition examination survey I epidemiologic follow-up study[J]. Cancer Res, 1988,48(2):452-458.
[23]	Calabresi L, Rossoni G, Gomaraschi M , et al. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-α content and enhancing prostaglandin release[J]. Circ Res, 2003,92(3):330-337. DOI: 10.1161/01.res.0000054201.60308.1a.
[24]	Langsenlehner U, Krippl P, Renner W , et al. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk[J]. Breast Cancer Res Treat, 2005,90(2):113-115. DOI: 10.1007/s10549-004-3607-7.
[25]	Flote VG, Frydenberg H, Ursin G , et al. High-density lipoprotein-cholesterol, daily estradiol and progesterone, and mammographic density phenotypes in premenopausal women[J]. Cancer Prev Res (Phila), 2015,8(6):535-544. DOI: 10.1158/1940-6207.CAPR-14-0267.
[26]	Fiorenza AM, Branchi A, Sommariva D . Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects[J]. Int J Clin Lab Res, 2000,30(3):141-145. DOI: 10.1007/s005990070013.
[27]	Knapp ML, al-Sheibani S, Riches PG . Alterations of serum lipids in breast cancer: effects of disease activity, treatment, and hormonal factors[J]. Clin Chem, 1991,37(12):2093-2101.
[28]	Henriksson P, Eriksson M, Ericsson S , et al. Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate[J]. Lancet, 1989,2(8673):1178-1180. DOI: 10.1016/s0140-6736(89)91790-X.
[29]	Kökoğlu E, Karaarslan I, Karaarslan HM , et al. Alterations of serum lipids and lipoproteins in breast cancer[J]. Cancer Lett, 1994,82(2):175-178. DOI: 10.1016/0304-3835(94)90008-6.
[30]	Duffy MJ, Evoy D, Mcdermott EW , et al. CA 15-3: uses and limitation as a biomarker for breast cancer[J]. Clin Chim Acta, 2010,411(23-24):1869-1874. DOI: 10.1016/j.cca.2010.08.039. doi:10.1016/j.cca.2010.08.039
[31]	Duffy MJ . CA 15-3 and related mucins as circulating markers in breast cancer[J]. Ann Clin Biochem, 1999,36(Pt 5):579-586. DOI: 10.1177/000456329903600503.
[32]	Ogata S, Maimonis P, Itzkowitz SH , et al. Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity[J]. Cancer Res, 1992,52(17):4741-4746.
[33]	Nath S, Mukherjee P . MUC1: a multifaceted oncoprotein with a key role in cancer progression[J]. Trends Mol Med, 2014,20(6):332-342. DOI: 10.1016/j.molmed.2014.02.007.
[34]	Pitroda SP, Khodarev NN, Beckett MA , et al. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment[J]. Proc Natl Acad Sci U S A, 2009,106(14):5837-5841. DOI: 10.1073/pnas.0812029106. doi:10.1073/pnas.0812029106
[35]	Wang HH, Afdhal NH, Gendler SJ , et al. Evidence that gallbladder epithelial mucin enhances cholesterol cholelithogenesis in MUC1 transgenic mice[J]. Gastroenterology, 2006,131(1):210-222. DOI: 10.1053/j.gastro.2006.04.011. doi:10.1053/j.gastro.2006.04.011